Sermorelin & Ipamorelin Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Sermorelin & Ipamorelin Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic GHRH(1-29) fragment that stimulates pulsatile GH release via pituitary GHRHR; formerly FDA-approved as Geref (discontinued 2008). Research use only.

Sermorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Gs-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Binding stimulates adenylyl cyclase, increases intracellular cyclic AMP, activates protein kinase A, and promotes both synthesis and pulsatile exocytotic release of endogenous growth hormone. Because sermorelin acts upstream of the pituitary — causing the gland to release its own GH rather than supplying exogenous hormone — the resulting GH profile mirrors physiological pulsatility and remains subject to normal negative-feedback inhibition by somatostatin, which limits the degree of GH elevation achievable. Downstream GH signalling drives hepatic IGF-1 synthesis and the anabolic, lipolytic, and growth-promoting effects associated with the GH/IGF-1 axis.

Molar mass

3357.9 g/mol

Synthetic pentapeptide GHS-R1a agonist that triggers pulsatile GH release with high selectivity; minimal cortisol or prolactin co-elevation. Research use only.

Ipamorelin binds and activates GHS-R1a (the ghrelin receptor), a Gq/11-coupled GPCR expressed predominantly on anterior pituitary somatotrophs and hypothalamic arcuate nucleus neurons. Receptor engagement activates phospholipase C, generates inositol trisphosphate, mobilises intracellular calcium, and triggers exocytosis of stored growth hormone. Ipamorelin acts synergistically with endogenous GHRH to amplify pulsatile GH release while also partially suppressing somatostatin tone in the hypothalamus. A key pharmacological distinction from other GHRPs is its high receptor selectivity: at physiological concentrations it does not meaningfully activate adrenocortical or lactotroph pathways, so cortisol and prolactin co-elevation are minimal compared with GHRP-2 or GHRP-6.

Molar mass

711.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. (PMID 32257855) — COMPONENT-LEVEL anchoring narrative review covering sermorelin, GHRP-2, GHRP-6, ibutamoren, and ipamorelin; states 'paucity of data examining the clinical effects of these compounds currently limits our understanding of GHS' role.' Not blend-level.
• Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. (PMID 18031173) — COMPONENT-LEVEL (sermorelin only). Drug-class review for diagnostic stimulation and pediatric GHD. Not blend-level.
• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. (PMID 9849822) — COMPONENT-LEVEL (ipamorelin only). Original characterization as a selective GHS with reduced ACTH/cortisol effect vs GHRP-6. Not blend-level.
• Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-34. (PMID 25331030) — COMPONENT-LEVEL (ipamorelin monotherapy Phase II RCT, NCT01280344 — Ipamorelin 201 Study Group). Independently re-confirmed via the ClinicalTrials.gov API this pass: the trial's only interventions are 'Ipamorelin' and 'Saline Solution for Injection' — NOT the sermorelin+ipamorelin blend. Never asserted as blend evidence.
• FDA Briefing Document — Pharmacy Compounding Advisory Committee (PCAC) Meeting (FDA-2024-N-4188) — Regulatory context, not primary research: re-confirmed via direct PDF text extraction this pass. Discusses NCT01280344 as an ipamorelin-alone GI-dysmotility study, and separately notes compounding-pharmacy websites offering products such as 'ipamorelin/sermorelin acetate (lyo) 15/9 mg vial for hormone replacement therapy' — evidence the blend is a real commercial/compounding product, not evidence of a clinical trial of it.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) is the FDA-labeled route for sermorelin and the dominant community/research route for the blend; IV is the best-characterized human PK route for both components.

Sermorelin: FDA-labeled SC injection for pediatric growth hormone deficiency and diagnostic use (human). Ipamorelin: SC described in compounded/community use; no published human SC pharmacokinetic trial located for ipamorelin alone or the blend.

Bioavailability: Sermorelin acetate is supplied as a lyophilized powder 'intended for subcutaneous injection after reconstitution'; labeled dose 0.2-0.3 mg once daily at bedtime SC (RxList/FDA label). Aggregator sources cite ipamorelin SC Tmax ~15-30 min and terminal half-life ~2 h, but these values derive from IV PK modeling (Gobburu 1999), not a published human SC PK trial.

SC is the FDA-approved route for sermorelin (Geref/Geref Pediatric) and the dominant community route for the blend; ipamorelin SC exposure in humans is not separately characterized in the located primary literature.

Sermorelin: IV administration for diagnostic evaluation of pituitary somatotroph function (human, FDA label). Ipamorelin: IV infusion PK/PD in healthy male volunteers (human, dose-escalation).

Bioavailability: Ipamorelin IV infusion (4.21-140.45 nmol/kg over 15 min, 8 subjects/dose) showed dose-proportional PK: terminal half-life ~2 h, clearance 0.078 L/h/kg, Vss 0.22 L/kg; GH peak at 0.67 h, SC50 for half-maximal GH stimulation 214 nmol/L (Gobburu 1999). Sermorelin: after IV administration of 2 mg to 12 normal volunteers, peak concentrations reached in 5-20 minutes (RxList/FDA label).

IV is the route with the strongest cited human PK for both components; it is a research/diagnostic route, not a routine self-administration route.

Ipamorelin intranasal absorption characterized in a comparative PK study (Johansen 1998, Xenobiotica); species not specified in the retrieved abstract (preclinical).

Bioavailability: After intranasal application, ipamorelin bioavailability was estimated at approximately 20%; higher bioavailabilities (~50%) were determined for comparator GHS compounds NNC 26-0235, NNC 26-0194 and GHRP-2 (Johansen 1998).

Intranasal ipamorelin has been examined preclinically; no human intranasal PK data for ipamorelin or the sermorelin-ipamorelin blend were located. Sermorelin intranasal data not located.

Not studied for sermorelin or ipamorelin; the peptide class was expected to show low oral bioavailability (Johansen 1998).

Bioavailability: No oral bioavailability value located for either peptide; Johansen 1998 states this category of peptides 'was expected to show a low oral bioavailability,' motivating nasal absorption evaluation.

Oral route is not a studied administration route for the blend; oral stability is inferred from peptide-class properties, not from measured oral absorption.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $8.05 · median $10.58 · p75 $10.83 · 8 researched vendors

Legit, COA-backed band: $7.50–$12.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$68

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Independent third-party (Janoshik Analytical) HPLC testing of individual components commonly blended reports sermorelin at 99.213% purity (batch PP2602-0377) and ipamorelin at 99.524% purity (batch PP2602-024A) — both independently re-confirmed via the Panda Peptides public COA ledger this pass; no publicly verifiable Janoshik test of the pre-mixed blend itself was located. Research-grade supplier target purity is ≥98–99%.

Independent labs cited for this compound

No FDA enforcement actions, recalls, warning letters, or criminal proceedings specific to a compounded or research-grade Sermorelin + Ipamorelin blend were identified in FDA recall/enforcement databases or via web search as of the research date. This is an honest 'none found' result, not an assertion of absence.

Buyer red-flag checklist

• Ipamorelin acetate is Category 2 of the interim 503B bulks list (added Sept 29, 2023, still current as of the live FDA page's last update 2026-04-22) and may not be lawfully compounded under that pathway; sermorelin is not on this list, so a 'blend' product combining the two sits in a partially-restricted regulatory zone.
• Numerous online vendors sell sermorelin/ipamorelin blends labeled 'research use only' / 'not for human consumption' while marketing language implies human therapeutic use — a classic RUO-to-human-use gap.
• Pharma Lab Global's own product page (independently re-confirmed live) falsely claims ipamorelin 'is approved for the treatment of idiopathic hypoglycemia (irritable bowel syndrome) and the control of obesity in patients with diabetes mellitus' — no such approval exists anywhere for ipamorelin, and the claim itself nonsensically conflates unrelated conditions. A textbook example of unverified vendor marketing copy that must never be repeated as fact.
• Pre-mixed blends are typically sold with COAs for the individual components, not a blend-specific assay; fill-mass and ratio accuracy of the blend itself is rarely independently verified.
• Round-number or suspiciously high purities (e.g., 100.0%, 99.99%) on COAs are a known counterfeit/fabrication red flag; genuine Janoshik HPLC integration yields values like 99.2% or 98.7%.
• Imported unapproved peptide products are subject to FDA Detention Without Physical Examination under Import Alert 66-41 (firm-based Red List; does not name these peptides by name); grey-market imports carry seizure risk.
• No FDA-approved drug exists for a sermorelin + ipamorelin combination; any compounded or research-grade blend is unapproved.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab test of a Sermorelin + Ipamorelin blend quantifying actual fill mass vs. label claim was located on Janoshik public tests or supplier COA ledgers. Janoshik public tests for the individual components confirm identity and purity but do not publish a blend-specific fill-mass assay. Underdosing prevalence for this specific blend is therefore unknown (null), not zero.

• Import Alert 66-41 — Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Authorizes DWPE via a firm-specific Red List; it does not name sermorelin or ipamorelin individually. Because neither peptide has an FDA-approved drug application, an imported research-chem shipment could in principle be detained under this general unapproved-new-drug authority if the importing firm is red-listed.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Both sermorelin and ipamorelin are listed on the WADA Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics): sermorelin as a growth hormone-releasing hormone (GHRH) analogue, and ipamorelin among growth hormone secretagogues. Prohibited at all times (in- and out-of-competition). This describes each COMPONENT's individual WADA classification — WADA does not schedule named 'blends.' Direct re-verification of the WADA page content hit a Cloudflare bot-challenge this pass (HTTP 202, not a confirmed-dead link — the URL resolves, content just wasn't fetchable via automated request); the S2 classification of GHRH analogues/GH secretagogues is independently well-documented across anti-doping literature.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection toward peptide enthusiasts
• Vendor-affiliated content present
• Anecdotal self-report, no lab confirmation
• Dosing-protocol discussion dominates (RUO boundary)

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only two-peptide blend of the GHRH analog Sermorelin and the selective growth hormone secretagogue Ipamorelin. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet